CHRONIC TOTAL OCCLUSIONS: WHAT IS KNOWN AND

Slides:



Advertisements
Similar presentations
Impact of Diabetes Mellitus on Early and Long-term Results of Percutaneous Drug- eluting Stent Implantation for Unprotected Left Main Coronary Disease.
Advertisements

When PCI in NSTEMI? Giuseppe Biondi Zoccai, MD Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome.
STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.
Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany BSIC, Manchester, September 15, 2006.
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy Educational Fellowship in PCI.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Pros and cons of FFR in multivessel disease: from FAME to ACS Giuseppe Biondi Zoccai University of Modena and Reggio Emilia, Modena, Italy
Debate #4: CTO Revascularization
Biondi-Zoccai: Peripheral interventions – metcardio.org Basic principles of peripheral interventions Giuseppe Biondi Zoccai University.
Complex Coronary Cases Supported by: Abbott Vascular Boston Scientific Corporation Medtronic, Inc. Astrazeneca.
PCI vs. CABG: Review of the evidence and suggestions Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy.
Retrograde Percutaneous Recanalization Of Coronary Chronic Total Occlusions: Outcomes And Technical Tips & Tricks From 17 Patients G. BIONDI-ZOCCAI, C.
Retrograde approach for the Recanalizaiton of Coronary CTO: Preliminary Experience of Single Centre Lei Ge, Juying Qian, Xuebo Liu, Qin Qing, Junbo Ge.
Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.
Multivessel PCI on top of culprit lesion revascularization? No way!
COMPLETE REVASCULARIZATION IN ELDERLY - When it’s contraindicated
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy JOINT SYMPOSIUM WITH JACCT - Bologna, 25/9/2008.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.
Can we improve the management of angina patients after percutaneous coronary intervention? Beneficial effects of adding trimetazidine MR therapy after.
Chronic Total Occlusions
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Multivessel Coronary Artery Disease
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Retrograde Techniques and the Impact of Operator.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Novel Modification of the Retrograde Approach.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
G. Capretti, M. Carlino, A. Colombo, L. Azzalini
Dr. Bradley Strauss CIHR Team in Vascular Occlusive Disease
Interesting Case Presentation
The MASS-DAC Study.
NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.
Treating CTOs Is there evidence based data?
Meruzhan Saghatelyan, MD, Interventional cardiologist
Crossing SFA-Popliteal Artery CTO’s
Clinical need for determination of vulnerable plaques
Case presentation: Critical Limb Ischemia
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
Subintimal Tracking and Reentry for CTO STAR Method
On behalf of J. Belardi, M. Leon, L. Mauri,
Mortality Related to Periprocedural MI in CTO-PCI
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
Trends in Coronary Procedures per 1000 Medicare Beneficiaries
Giuseppe Biondi Zoccai
Giuseppe Biondi Zoccai
Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,
Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.
Giuseppe Biondi Zoccai, MD
3-Year Clinical Outcomes From the RESOLUTE US Study
Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 
Peter K. Smith, MD  The Annals of Thoracic Surgery 
AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY.
P. Omedé,1 A. Abbate,4 G. P. Trevi,1 and I. Sheiban1
Benefits of complete coronary revascularization – Counterpoint: what are you talking about? Giuseppe Biondi Zoccai, MD University of Modena and Reggio.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
(p = 0.32 for noninferiority)
PREDICTORS OF ADVERSE EVENTS IN PATIENTS WITH UNPROTECTED LEFT MAIN DISEASE TREATED WITH DRUG-ELUTING STENTS: EVIDENCE FROM A COLLABORATIVE META-REGRESSION.
Single Versus Multiple Vessel Stenting In Patients With St-Elevation Myocardial Infarction: Results From A 30,886-Patient Meta-Analysis Giuseppe Biondi.
ORAL CILOSTAZOL TREATMENT PREVENTS RESTENOSIS AND MAJOR ADVERSE CLINICAL EVENTS AFTER DRUG-ELUTING STENT IMPLANTATION: EVIDENCE FROM A META-ANALYSIS G.
Comparison of radial versus femoral access in patients undergoing invasive management for acute coronary syndromes: evidence from a systematic review and.
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
The American College of Cardiology Presented by Dr. A. Abazid
Alfredo R. Galassi et al. JCIN 2016;9:
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
The Clinical Significance and Management Implications of Chronic Total Occlusion Associated With Surgical Coronary Artery Revascularization  Lorenzo Azzalini,
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

CHRONIC TOTAL OCCLUSIONS: WHAT IS KNOWN AND WHAT IS UNKOWN Giuseppe Biondi Zoccai University of Turin, Turin, Italy gbiondizoccai@gmail.com 4th International Interventional Forum – Turin 26-27 February 2009

LEARNING OBJECTIVES What is known What is unknown Prevalence of chronic total occlusions (CTO) Pathophysiologic basis and clinical impact Possible techniques What is unknown When is revascularization indicated? If yes, which type of revascularization? Which technique? Which stent?

LEARNING OBJECTIVES What is known What is unknown Prevalence of chronic total occlusions (CTO) Pathophysiologic basis and clinical impact Possible techniques What is unknown When is revascularization indicated? If yes, which type of revascularization? Which technique? Which stent?

INCIDENCE AND IMPACT

CLUSTERING WITH MULTIVESSEL DISEASE

LEARNING OBJECTIVES What is known What is unknown Prevalence of chronic total occlusions (CTO) Pathophysiologic basis and clinical impact Possible techniques What is unknown When is revascularization indicated? If yes, which type of revascularization? Which technique? Which stent?

CORONARY OCCLUSION AND MYOCARDIAL APOPTOSIS

COLLATERALS MOST OFTEN FAIL TO PREVENT SYMPTOMATIC ISCHEMIA 1 0,9 0,8 0,7 0,6 sens 0,5 spec 0,4 0,3 0,2 0,1 0,00 0,09 0,13 0,16 0,17 0,21 0,25 0,28 0,31 0,34 0,36 0,38 0,40 0,42 0,43 0,47 0,69 1,00 FFRcoll Moretti et al, J Cardiovasc Med 2008 – in press

PCI MAY PROVIDE CARDIAC REMODELING BENEFITS Before PCI for CTO 5 months after PCI for CTO Baks et al, J Am Coll Cardiol 2006;47:721-725

LONG-TERM DATA FROM NON-RANDOMIZED STUDIES SUPPORT THE BENEFITS OF PCI FOR CTO Especially for LAD CTO Suero et al, J Am Coll Cardiol 2001;38:409-14; Safley et al, J Am Coll Cardiol Intv 2008;1:295-302

LEARNING OBJECTIVES What is known What is unknown Prevalence of chronic total occlusions (CTO) Pathophysiologic basis and clinical impact Possible techniques What is unknown When is revascularization indicated? If yes, which type of revascularization? Which technique? Which stent?

POSSIBLE TECHNIQUES Standard antegrade Parallel wire Drilling wire Retrograde CART IVUS-guided puncture Subintimal IVUS STAR Micro-channel injection

POSSIBLE DEVICES Standard wires Monorail or OTW balloon Stent CTO wires (eg Asahi’s, Shinobi) Microcatheters Tornus Frontrunner Crosser Safecross

LEARNING OBJECTIVES What is known What is unknown Prevalence of chronic total occlusions (CTO) Pathophysiologic basis and clinical impact Possible techniques What is unknown When is revascularization indicated? If yes, which type of revascularization? Which technique? Which stent?

INTERVENTIONISTS’ NEW OATH: I WILL NOT TREAT CTO Hochman, New Engl J Med 2006;355:2395-2407

SHOULD THUS INTERVENTIONISTS BE DISCOURAGED? Boden et al, New Engl J Med 2007;356:1503-1516

IS ANY SYNTHESIS POSSIBLE? Abbate et al, J Am Coll Cardiol 2008;51:956-64

IS ANY SYNTHESIS POSSIBLE? Schomig et al, J Am Coll Cardiol 2008;52:894-904

LEARNING OBJECTIVES What is known What is unknown Prevalence of chronic total occlusions (CTO) Pathophysiologic basis and clinical impact Possible techniques What is unknown When is revascularization indicated? If yes, which type of revascularization? Which technique? Which stent?

Serruys et al, New Engl J Med 2009;360:961-72 A SYNTAX FOR EVIDENCE Serruys et al, New Engl J Med 2009;360:961-72

LEARNING OBJECTIVES What is known What is unknown Prevalence of chronic total occlusions (CTO) Pathophysiologic basis and clinical impact Possible techniques What is unknown When is revascularization indicated? If yes, which type of revascularization? Which technique? Which stent?

BEGIN WITH A THOROUGH BUT SIMPLE APPROACH, BUT BE READY FOR ESCALATION Dedicated CTO wires Contralateral injection Parallel wires Drilling wire Retrograde approach CART Microcatheter Tornus

LEARNING OBJECTIVES What is known What is unknown Prevalence of chronic total occlusions (CTO) Pathophysiologic basis and clinical impact Possible techniques What is unknown When is revascularization indicated? If yes, which type of revascularization? Which technique? Which stent?

USE DES WHENEVER POSSIBLE, BUT WHICH DES EXACTLY?

TAKE HOME MESSAGES

TAKE HOME MESSAGES CTO are highly prevalent and have a significant clinical and management impact It is thus paramount to appropriately risk-stratify each patient depending on his baseline and angiographic features, to clarify the clinical indication for CTO recanalization Several types of interventional techniques and devices are currently available for CTOs Improvements in stents (ie drug-elution), wires (ie dedicated wire for CTOs) and ancillary devices (eg microcatheters) together with new or refined techniques have improved acute and long-term results of PCI for CTOs